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Several studies have shown that MA is involved in the progression of chronic kidney disease. However,
it is unclear if there is also a relationship between serum bicarbonate and graft function after kidney
transplantation (KTx). We hypothesized that low serum bicarbonate is associated with a lower estimated
glomerular filtration rate (eGFR) 1 year after KTx. METHODS: We performed a post hoc analysis
of a single-center, open-label randomized trial in 90 KTRs and investigated the relationship of serum
bicarbonate and graft function in the first year after KTx. RESULTS: Prevalence of MA was high after
KTx (63%) and decreased to 28% after 1 year. Bicarbonate (20.6 ± 3.0 to 22.7 ± 2.7 mmol/L) increased
in the first year after transplantation whereas eGFR (53.4 ± 15.8 to 56.9 ± 18.5 mL/min/1.73 m2) did
not change significantly. Higher serum bicarbonate (p = 0.029) was associated with higher eGFR in the
first year after KTx. CONCLUSION: Prevalence of MA is high in KTRs. In the first year after KTx,
serum bicarbonate was positively correlated with eGFR, suggesting a potential role of MA in kidney graft
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Abstract
Background: Metabolic acidosis (MA) is common in kidney transplant recipients (KTRs). Sev-
eral studies have shown that MA is involved in the progression of chronic kidney disease. How-
ever, it is unclear if there is also a relationship between serum bicarbonate and graft function 
after kidney transplantation (KTx). We hypothesized that low serum bicarbonate is associated 
with a lower estimated glomerular filtration rate (eGFR) 1 year after KTx. Methods: We per-
formed a post hoc analysis of a single-center, open-label randomized trial in 90 KTRs and in-
vestigated the relationship of serum bicarbonate and graft function in the first year after KTx. 
Results: Prevalence of MA was high after KTx (63%) and decreased to 28% after 1 year. Bicar-
bonate (20.6 ± 3.0 to 22.7 ± 2.7 mmol/L) increased in the first year after transplantation where-
as eGFR (53.4 ± 15.8 to 56.9 ± 18.5 mL/min/1.73 m2) did not change significantly. Higher serum 
bicarbonate (p = 0.029) was associated with higher eGFR in the first year after KTx. Conclusion: 
Prevalence of MA is high in KTRs. In the first year after KTx, serum bicarbonate was positively 
correlated with eGFR, suggesting a potential role of MA in kidney graft function.
© 2019 The Author(s)
Published by S. Karger AG, Basel
Introduction
Metabolic acidosis (MA), usually defined as a low pH and low serum bicarbonate levels 
(< 22 mmol/L), is a typical complication in kidney transplant recipients (KTRs), with a preva-
lence of 12–58% [1]. Compared to chronic kidney disease (CKD) patients with similar renal 
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function, MA seems to be consistently more common and more severe in KTRs [1–3]. Specif-
ically, in the time directly after transplantation, MA is frequent because of calcineurin inhib-
itor nephrotoxicity, acute rejection, suboptimal allograft function, and ischemic tubular 
dysfunction [3, 4]. Among these factors, donor-specific conditions like age and the type of 
transplant might play an important role [1]. 
MA has been associated with a variety of complications such as anemia, uremic bone 
disease, protein-energy wasting, increased inflammatory mediators, insulin resistance, and 
the impairment of myocardial function as well as disturbances in mineral metabolism, growth 
hormone production, and thyroid gland function [5–8]. Additionally, acidosis and transplan-
tation are associated with an increased risk of bone disturbances [9]. 
Observational studies have shown that MA is associated with increased mortality in both 
dialysis patients and patients with nondialysis-dependent CKD [10]. Furthermore, over the 
past few years, it has been reported that MA may play an important role in the progression of 
CKD and that low serum bicarbonate levels are associated with a higher risk of progressing 
to end-stage renal disease [6, 10–15]. Consequently, the treatment of MA in CKD patients with 
alkalinizing agents or fruit and vegetables has been found to delay the progression of 
glomerular filtration rate (GFR) loss [16–19]. 
Recently, a first retrospective cohort study evaluated the prevalence, longitudinal trends, 
and risk factors for MA in KTRs [20], but there were several limitations. First, only one-quarter 
of the grafts were from deceased donors. Second, the cohort was comparatively healthy, with 
a low number of graft losses in the observed time period. 
We wanted to test the association of serum bicarbonate levels and graft function in a 
representative transplantation cohort in Switzerland. We hypothesized that low serum bicar-
bonate is associated with a lower estimated (e)GFR 1 year after kidney transplantation (KTx). 
Methods
Patients and Study Design
This study is the post hoc analysis of a previously conducted single-center, parallel-
group, open-label, randomized clinical trial performed in an academic setting at the University 
Hospital Zurich (Switzerland) that tested denosumab for its effects on bone mineral density 
in 90 KTRs. Details of the POSTOP (Prolia for Osteoporosis of Transplant Operated Patients) 
study were reported previously [21, 22]. The study was designed and conducted according 
to the International Conference on the Harmonization of Good Clinical Practice standards, 
approved by the local Ethics Committee (IRB approval No. 2011-0032), and registered on 
ClinicalTrials.gov (NCT01377467).  
Briefly, we recruited a total of 90 KTRs > 18 years that had undergone KTx < 28 days prior 
to examine the changes in bone mineral density over 1 year. Although half of the patients 
were treated with denosumab, all patients were included in this post hoc analysis since there 
is no evidence of any direct effects of denosumab on acid-base homeostasis. Nonetheless, we 
corrected all models for the randomization group to eliminate potential effects of denosumab 
on the outcome. Patients received standard triple immunosuppression including a calci-
neurin inhibitor (cyclosporine or tacrolimus), mycophenolate, and steroids. Induction 
treatment was performed with basiliximab or antithymocyte globulin according to the 
standard care protocol for KTRs at our center [21].
We investigated the relationship of serum bicarbonate levels and graft function in the 
first year after KTx. MA was defined as a serum bicarbonate level < 22 mmol/L. Graft function 
was determined by eGFR according to the 2009 CKD-EPI creatinine equation. Values were set 
to missing if patients had been treated for MA 1 month before the measurement (if not 
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otherwise indicated). Blood samples were taken at baseline (on average 15 days after KTx) 
and at 3, 6, and 12 months thereafter. 
Statistical Analyses
eGFR and bicarbonate differences between baseline and 12 months were compared with 
the Wilcoxon signed-rank test. eGFR was analyzed using a linear mixed model with random 
intercept. Treatment group (denosumab) versus control group (no denosumab), age at time 
of transplantation, donor status (living vs. deceased), and bicarbonate (not set to missing for 
Table 1. Baseline and 1-year characteristics of the entire cohort
At baseline At 1 year p value 
Total number of patients 90 90 –
Mean age, years (SD) 49.5 (13.4) – –
Male 57 (63.3) – –
Ethnicity
Caucasian 86 (95.6) – –
Asian 2 (2.2) – –
African 1 (1.1) – –
Other 1 (1.1) – –
ESRD diagnosis
Chronic glomerulonephritis 30 (33.3) – –
Diabetic nephropathy 7 (7.8) – –
Vascular nephropathy 8 (8.9) – –
Polycystic kidney disease 20 (22.2) – –
Other hereditary diseases 5 (5.6) – –
Other 20 (22.2) – –
Deceased donor 44 (48.9) – –
Graft loss 1 (1.1) – –
Rejection 8 (8.9)
Repeat transplantation 14 (15.6) – –
Randomization: denosumab 46 (51.1) – –
Dialysis mode
Hemodialysis 57 (63.3) – –
Peritoneal dialysis 16 (17.8) – –
Pre-emptive transplantation 17 (18.9) – –
Cyclosporine 26 (28.9) 19 (21.3) –
Tacrolimus 64 (71.1) 70 (78.7) –
Induction therapy1 89 (98.9) – –
Mean body mass index (SD) 25.7 (5.0) 25.8 (4.8) 0.287
Mean eGFR, mL/min/1.73 m2 (SD) 53.3 (15.8) 56.9 (18.5) 0.303
Mean bicarbonate, mmol/L (SD) 20.6 (3.0) 22.7 (2.6) <0.001
Mean sodium, mmol/L (SD) 138.1 (3.7) 139.3 (2.8) 0.048
Mean chloride, mmol/L(SD) 105.9 (4.2) 104.6 (2.9) 0.022
Mean calcium, mmol/L (SD) 2.3 (0.2) 2.5 (0.2) <0.001
Mean phosphate, mmol/L (SD) 0.6 (0.2) 0.9 (0.3) <0.001
Mean magnesium, mmol/L (SD) 0.6 (0.1) 0.7 (0.1) 0.001
Mean PTH, ng/L (SD) 156.2 (145.8) 105.5 (75.6) <0.001
All values are displayed as n (%), if not otherwise stated. The following values were set to missing for 1 
patient who was treated for metabolic acidosis 1 month before measurement at baseline and for 4 patients 
at 1 year: body mass index, PTH, calcium, phosphate, eGFR, bicarbonate, magnesium, sodium, and chloride.
1 Patients received basiliximab (68.9%) or antithymocyte globulin (30.0%).
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patients treated with alkali therapy) were included as fixed effects. The restricted maximum 
likelihood method was used to estimate the parameter values of the linear mixed model. The 
comparison between a random intercept model and a random intercept and random slope 
(for bicarbonate) model indicated that the random intercept and random slope model did not 
perform better. Assumptions of the within-group error were checked with plots of the stan-
dardized residuals versus fitted values and a Q-Q plot of the standardized residuals. Assump-
tions of the random effects were assessed by a Q-Q plot of the random effects. All analyses 
were performed in the R programming language v3.3.3 (R Core Team, 2017) and SPSS v20 
(IBM Corp.). The nlme package [23] was used to run the linear mixed model.
Results
Baseline Characteristics
Demographic and baseline characteristics of the study population are presented in Table 
1. The mean age of the study cohort was 49.5 ± 13.4 years and 57 (63%) were male. The 
majority were undergoing KTx for the first time (84%) and were of Caucasian origin (96%). 
Most patients were on renal replacement therapy before KTx (81%) and 17 (19%) underwent 
pre-emptive transplantation. Maintenance immunosuppression consisted of calcineurin 
inhibitor (tacrolimus 71% or cyclosporine 29%) combined with mycophenolate and pred-
nisone. Half of the patients were treated with denosumab as part of the POSTOP study protocol 
[21]; 44/90 kidney transplants (49%) were from deceased donors. Mean eGFR at baseline 
was 53.3 ± 15.8 mL/min/1.73 m2 and mean bicarbonate was 20.6 ± 3.0 mmol/L.
Prevalence of MA Decreased in the First Year after KTx
Serum bicarbonate levels increased continuously from 20.6 ± 3.0 mmol/L at baseline 
(11± 8 days after KTx) to 22.7 ± 2.6 mmol/L (p < 0.001) in the first year after KTx (Fig. 1a). In 
Fig. 1. Bicarbonate (A) and eGFR (B) (CKD-EPI 2009) at months 0, 3, 6, and 12. For months 0, 3, 6, 12 there 
were 87, 59, 72, and 75 valid data for bicarbonate and 89, 85, 87, and 84 for eGFR (CKD-EPI 2009), respec-
tively. Values were set to missing for patients treated with alkali therapy. Errors bars show the standard de-
viation.
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parallel, eGFR levels had increased numerically from 53.3 ± 15.8 to 56.9 ± 18.5 mL/min (p = 
0.303) 1 year after KTx (Fig. 1b). 
The prevalence of MA, defined as serum bicarbonate < 22 mmol/L, was highest directly 
after KTx (63%) and declined over the first year post-KTx to 28% (Fig. 2). There was no 
difference in the prevalence of MA depending on the respective calcineurin inhibitor included 
in the immunosuppressive regimen of the study participants. 
Higher Serum Bicarbonate Levels Are Associated Positively with eGFR within the First 
Year after KTx
In Figure 3, eGFR and serum bicarbonate levels of each individual patient at different 
time points are shown. Interestingly, we observed different patterns and strong interindi-
vidual variations in the eGFR and bicarbonate profiles in the first year after KTx. Additionally, 
a heat map indicated, by darker coloring, the regions with the highest density of values (bicar-
bonate and the corresponding eGFR) (Fig. 4).
A linear mixed model with random intercept adjusted for age, serum bicarbonate levels, 
donor status (living vs. deceased), and randomization (POSTOP trial) was used for further 
analysis. Higher serum bicarbonate levels (p = 0.029) were associated with higher eGFR 
values within the first year after KTx. Randomization (p = 0.786) of the POSTOP trial, younger 
age (p = 0.063), and donor status (p = 0.821) were not associated with eGFR over the first year 
after KTx. 
Discussion
MA is a frequent condition in CKD and has been associated with various clinical compli-
cations. Recently, the impact of MA on the progression of kidney function in CKD patients and 
the beneficial effect of alkali therapy on CKD progression has gained in importance. Interest-
Fig. 2. Prevalence of metabolic 
acidosis over the course of 1 year 
after kidney transplantation in all 
patients. 
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ingly, despite the high prevalence of MA in KTRs, only few data exist regarding the impact of 
MA on graft outcome after KTx. We performed a post hoc analysis of a previously performed 
single-center, parallel-group, open-label, randomized clinical trial [21], and investigated the 
relationship between serum bicarbonate levels and eGFR over the first year after KTx. Our 
study presents evidence that serum bicarbonate levels are positively associated with eGFR in 
the first year after KTx. 
In our study, the prevalence of MA, defined as serum bicarbonate < 22 mmol/L, was 
highest after KTx (63%) and declined over the first year post-KTx to 28%. According to the 
literature, the prevalence of MA after KTx ranges from 11 to 58.1% and occurs at higher eGFR 
levels than in CKD patients [1]. The prevalences reported in our cohort were highly concordant 
with previously published results. Messa et al. [1] reviewed 11 studies in which the preva-
Fig. 3. eGFR (CKD-EPI 2009) versus serum bicarbonate at months 0, 3, 6, and 12 after kidney transplantation 
in individual patients, demonstrating strong interindividual patterns of eGFR trajectory.
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lence of MA in KTRs was reported as between 11 and 58%. A large variation in prevalences 
across studies is mainly due to different study populations and definitions of MA. Interest-
ingly, a recent study by Park et al. [20] described a prevalence of MA of only 10% 1 year after 
KTx in a cohort of 2,318 adult Korean KTRs. However, compared to our cohort, the number 
of transplants from deceased donors was considerably lower (48 and 24%, respectively), 
which could explain the difference in the occurrence of MA. Due to the lack of larger, solid 
studies, it is not yet verified if donor characteristics (e.g., a living vs. a deceased donor) play 
a role in the incidence of MA after KTx. Nonetheless, in our study, the prevalence of MA was 
highest directly after KTx and further declined over the first year. This may indicate that 
donor-specific factors play a role in the development of MA, as previously stated by Messa et 
al. [1]. 
As expected, bicarbonate levels increased within the first year after KTx in our cohort 
whereas for eGFR no significant change was observed. Reduction of medication, particularly 
immunosuppression, and general stabilization of the kidney graft function may be the most 
important underlying causes for the increase in bicarbonate levels. Interestingly, in our 
cohort, the individual course of eGFR varied strongly between the 90 study participants. This 
strong variability has been previously reported [24, 25] and is not surprising, as many factors 
such as medication, donor characteristics, and general health status differ strongly not only 
between patients but also for the individual patient, and for medication. However, high vari-
ability of kidney function after KTx has been described as an independent risk factor for graft 
loss and death [24–26]. Thus, we used a mixed linear model including all available eGFR and 
bicarbonate values over the first year after KTx. In our analysis, higher serum bicarbonate 
levels were associated with higher eGFR within the first year after KTx. Importantly, our 
study is the first to include Caucasian kidney recipients that were treated according to a 
European standard transplant program, and it confirms previously published data on a 
Korean cohort by Park et al. [20].
Fig. 4. Scatter-plot depicting the 
correlation of eGFR (CKD-EPI 
2009) and serum bicarbonate 
over the first year after kidney 
transplantation in all patients. 
Darker areas highlight regions 
with the highest density of values.
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Several studies have reported that eGFR levels at 1 year after KTx are a strong predictor 
of long-term transplant outcomes [27–33]. Considering the positive association between 
bicarbonate and GFR levels, correction of MA in KTRs may have the potential to improve eGFR 
levels and, subsequently, the long-term graft outcomes. However, further randomized 
controlled interventional trials are required to demonstrate the beneficial effect of alkali 
therapy on transplant outcome.
Our study has several limitations. First, there was a relatively small number of partici-
pants, and serum bicarbonate measurements were not performed at each transplant visit. 
Furthermore, additional confounders emanating from the post hoc study design may have 
been present. Nonetheless, this design can also be seen as a strength, since study visits were 
scheduled prospectively according to the study protocol and patients were all seen at the 
same transplant center, producing high-quality data on a representative Swiss cohort. Finally, 
because of the study design, the results did not allow any conclusions regarding a causal rela-
tionship between serum bicarbonate and eGFR. 
In conclusion, MA is highly prevalent in KTRs and serum bicarbonate values are asso-
ciated with eGFR levels in the first year after KTx, suggesting a potential role of MA on kidney 
graft function. A randomized controlled interventional study would be desirable to prove a 
beneficial effect of alkali therapy on graft function in KTRs with MA.
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